AlgeriaTuberculosis profile
Population  2014 39 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4.4 (3.1–6.1) 11 (7.9–16)
Mortality (HIV+TB only) 0.046 (0.019–0.085) 0.12 (0.05–0.22)
Prevalence  (includes HIV+TB) 46 (23–76) 118 (59–196)
Incidence  (includes HIV+TB) 31 (25–37) 78 (64–94)
Incidence (HIV+TB only) 0.2 (0.15–0.26) 0.52 (0.39–0.67)
         
Case detection, all forms (%) 74 (62–90)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.4 (0.6–2.7) 9.1 (1.1–29)
MDR-TB cases among notified pulmonary
TB cases
120 (51–230) 51 (6–160)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 7 206   364
Pulmonary, clinically diagnosed 1 239   0
Extrapulmonary 13 708   0
       
Total new and relapse 22 517    
Previously treated, excluding relapses 198    
Total cases notified 22 715    
Among 6 767 new cases:
72 (1%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 509 (7%) 178 (32%) 693
Laboratory-confirmed RR-/MDR-TB cases     65
Patients started on MDR-TB treatment ***     56
TB/HIV 2014 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB 4 936  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (91) 7 020
Previously treated cases, excluding relapse, registered in 2013 (59) 130
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 2.2
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-27 Data: www.who.int/tb/data